[Gut microbiota-mediated FGF metabolic axis in the pathogenesis, prevention and treatment of various diseases].

Authors

Xianxi Ye, Zhuofan Lu, Weiru Zhang, Xuelian Liu, Hong Zheng

Published in

Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences. Pages 1-13. Sep 29, 2026. Epub Sep 29, 2026.

Abstract

The gut microbiota is pivotal in regulating host metabolic homeostasis and is closely associated with the onset, progression, prevention, and treatment of various diseases. Endocrine fibroblast growth factors (FGFs) serve as key signaling molecules through which the gut microbiota influences host metabolic health. Via microbial metabolites, the gut microbiota regulates signaling axes such as FXR-FGF15/19, PPARα-FGF21, and VDR-FGF23, thereby participating in host glucose and lipid metabolism, mineral homeostasis, and inflammatory responses. Gut microbiota-mediated FGF metabolic axes play critical roles in the development and progression of obesity, diabetes, liver disease, gastrointestinal disorders, kidney disease, and cardiovascular disease. Targeting the gut microbiota and FGF metabolic axes through probiotics, prebiotics, postbiotics, and microbiota-derived metabolites may therefore offer promising strategies for the prevention and treatment of these diseases. This review summarizes the mechanistic links between the gut microbiota and FGF metabolic axes, discusses their roles in disease development and progression, and highlights the potential of these mechanisms for developing preventive and therapeutic strategies.

PMID:
42852528
Bibliographic data and abstract were imported from PubMed on 09 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.